| Trial ID: | L0381 |
| Source ID: | IRCT20170628034786N4
|
| Associated Drug: |
Curcumin
|
| Title: |
Evaluation of the effectiveness of Curcumin on fatty liver disease in children
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NAFLD. <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
| Interventions: |
Intervention 1: Intervention group: Patients will receive a 40 or 80 mg nanomicelle sina curcumin soft gel daily for 8 weeks. Intervention 2: Control group: The placebo will be taken once a day , which is quite similar in color and size to the main medici
|
| Outcome Measures: |
Serum level of Alanine aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase.;Serum level of Aspartate aminotransferase. Timepoint: 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of liver transaminase.Body mass index. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Measurement of height and weight and ratio of weight to square of height.;Fasting Blood Sugar. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Fasting Blood Sugar.;Lipid profile(Chol,TG,HDL,LDL). Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum lipid profile(Chol, TG, HDL,LDL).;Alkaline phosphatase. Timepoint: Before the intervention, 8 weeks after the initiation of treatment. Method of measurement: Quantitative measurement of serum Alkaline phosphatase.
|
| Sponsor/Collaborators: |
Esfahan University of Medical Sciences
|
| Gender: |
All
|
| Age: |
5 years16 years
|
| Phases: |
Phase 3
|
| Enrollment: |
60
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: During random allocation, patients will be divided into two groups of interventional and placebo by permutation block
|
| Start Date: |
04/07/2021
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 July 2021
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/57015
|
